Glenmark Pharma share rises 2% on securing USFDA nod; key details here

Q: How long will it take to read this news story?

The story "Glenmark Pharma share rises 2% on securing USFDA nod; key details here" has 414 words across 22 sentences, which will take approximately 2 - 4 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Glenmark Pharma share rises 2% on securing USFDA nod; key details here" was covered 2 days ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 118 news stories per day. It's most recent story was published 3 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #27208648</li><li>URL: https://chronographically.beamstart.com/news/glenmark-pharma-share-rises-2-17425341094051</li></ul>

Business Standard Logo Business Standard 2d ago

Glenmark Pharma share rises 2% on securing USFDA nod; key details here - Business Standard

Quick Summary:

Glenmark Pharma's stock rose after it said Glenmark Pharmaceuticals Inc., USA, has received final approval from the USFDA for its Olopatadine Hydrochloride Ophthalmic Solution USP, 0.

The 52-week high of Glenmark Pharma is Rs 1,830.05, while its 52-week low is Rs 936.05 per share.

Glenmark operates 11 state-of-the-art manufacturing facilities across four continents and conducts business in over 80 countries worldwide.